الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multiple myeloma - antineoplastična sredstva - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

accord healthcare s.l.u. - vorikonazol - aspergillosis; candidiasis; mycoses - antimycotics za sistemsko uporabo, triazol derivati - voriconazole je v širokem spektru, triazol protiglivično sredstvo, ter je označena pri odraslih in otrocih, starih dve leti ali več, kot sledi:zdravljenje invazivne aspergillosis;zdravljenje candidaemia v ne-neutropenic bolnikov;zdravljenje fluconazole-odporne resno invazivne candida okužbe (vključno c. krusei);zdravljenje hude glivične okužbe, ki jih povzročajo scedosporium spp. in oxysporum spp. voriconazole soglasju mora biti urejen, predvsem pri bolnikih z napredujočo, morda celo smrtno nevarne okužbe.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - karcinom, pljučni pljuč - antineoplastična sredstva - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioedem, dedno - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

gmp-orphan sa - trientine tetrahydrochloride - hepatolentikularna degeneracija - drugi zdravljene bolezni prebavil in presnove izdelki, - cuprior je primerna za zdravljenje wilsonova bolezen pri odraslih, mladostnikih in otrocih, ≥ 5 let nestrpni do d-penicillamine terapija.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinom, pljučni pljuč - antineoplastična sredstva - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

سلوفينيا - السلوفانية - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

norbrook laboratories (ireland) ltd -

سلوفينيا - السلوفانية - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

dopharma research -

سلوفينيا - السلوفانية - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceva santé animale -